Paul Scolardi · @super_trades
27th Apr 2015 from TwitLonger
$TRIL Cowen initiated Trillium with an Outperform and believes its SIRPFc molecule is a best-in-class therapy addressing a novel target, CD47, and is the only pure play on the CD47 target.
27th Apr 2015 from TwitLonger
$TRIL Cowen initiated Trillium with an Outperform and believes its SIRPFc molecule is a best-in-class therapy addressing a novel target, CD47, and is the only pure play on the CD47 target.